| Literature DB >> 31198075 |
Liangmei Chen1, Manyu Luodelete1, Changqing Dong1, Bing Li1, Weiguang Zhang2, Ping Nie1, Juan Liu1, Xiangmei Chen1, Ping Luo1.
Abstract
Background: To investigate the pathological spectrum of glomerular disease in patients with renal insufficiency (RI) from 2008 to 2017. Methods and results: We calculated the estimated glomerular filtration rate (eGFR) with the Chronic Kidney Disease Epidemiology Collaboration creatinine (CKD-EPI) equation and defined RI as an eGFR <60 ml/min/1.73 m2. A total of 969 RI patients were included in our study. IgA nephropathy (IgAN) was the most common subtype of primary glomerulonephritis (37.2%). The frequencies of IgAN and non-IgA mesangioproliferative glomerulonephritis decreased from 27.3% and 9.5% during 2008-2012 to 20.7% and 2.6% during 2013-2017, respectively. However, the frequency of membranous nephropathy increased from 6.8% to 16.2%. Lupus nephritis was the most common subtype of secondary glomerulonephritis (32.1%). The frequencies of both ANCA-associated systemic vasculitis and diabetic nephropathy increased from 3.8% to 7.6% and from 4.3% to 7.6%, respectively. The number of elderly patients (≥60 years) in our study increased sharply, from 15.6% in 2008 to 35.0% in 2017. Membranous nephropathy, minimal change disease, membranoproliferative glomerulonephritis, lupus nephritis and renal amyloidosis are more frequently observed in the elderly patients than in nonelderly patients (<60 years) (p < .05). Excluding those with acute kidney injury, IgAN was the leading cause of RI (24.9%), followed by membranous nephropathy (13.3%) and lupus nephritis (12.0%). Conclusions: IgAN and lupus nephritis were the most prevalent primary glomerulonephritis and secondary glomerulonephritis in patients with RI, respectively. The frequencies of membranous nephropathy, ANCA-associated systemic vasculitis and diabetic nephropathy increased significantly. The number of elderly patients with RI increased sharply.Entities:
Keywords: Glomerular disease; pathology; renal biopsy; renal insufficiency
Mesh:
Year: 2019 PMID: 31198075 PMCID: PMC6586151 DOI: 10.1080/0886022X.2019.1620774
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 2.606
Demographic and clinical characteristics of patients with renal insufficiency.
| Characteristics | Total, | Sex | ||
|---|---|---|---|---|
| Male, | Female, | |||
| eGFR, ml/min/1.73 m2, median | 37 | 39 | 36 | .551 |
| Age, years, median | 48 | 50 | 47 | .231 |
| Age stratification, | .154 | |||
| 15–49 | 507 (52.3) | 265 (49.6) | 242 (55.6) | |
| 50–59 | 204 (21.1) | 116 (21.7) | 88 (20.2) | |
| ≥60 | 258 (26.6) | 153 (28.7) | 105 (24.1) | |
| Time of kidney biopsy, | .405 | |||
| 2008–2009 | 149 (15.4) | 72 (13.5) | 77 (17.7) | |
| 2010–2011 | 169 (17.4) | 100 (18.7) | 69 (15.9) | |
| 2012–2013 | 167 (17.2) | 93 (17.4) | 74 (17.0) | |
| 2014–2015 | 232 (23.9) | 130 (24.3) | 102 (23.4) | |
| 2016–2017 | 252 (26.0) | 139 (26.0) | 113 (26.0) | |
Spectrum of glomerular disease in patients with renal insufficiency.
| Pathology type of glomerular disease | Number | Percentage |
|---|---|---|
| Primary glomerulonephritis | 611 | 63.1% |
| IgA nephropathy | 227 | 37.2% |
| Membranous nephropathy | 119 | 19.5% |
| Minimal change disease | 70 | 11.5% |
| Non-IgA mesangioproliferative glomerulonephritis | 53 | 8.7% |
| Focal segmental glomerulosclerosis | 74 | 12.1% |
| Membranoproliferative glomerulonephritis | 29 | 4.7% |
| Crescentic glomerulonephritis | 27 | 4.4% |
| Endocapillary proliferative glomerulonephritis | 12 | 2.0% |
| Secondary glomerulonephritis | 358 | 36.9% |
| Lupus nephritis | 115 | 32.1% |
| Henoch–Schönlein purpura nephritis | 17 | 4.7% |
| ANCA-associated systemic vasculitis | 58 | 16.2% |
| Malignant nephrosclerosis | 39 | 10.9% |
| Benign arteriolar nephrosclerosis | 38 | 10.6% |
| Thrombotic microangiopathy | 2 | 0.6% |
| Diabetic nephropathy | 60 | 16.8% |
| Light-chain deposition nephropathy | 8 | 2.2% |
| Renal amyloidosis | 12 | 3.4% |
| HBV-associated nephritis | 9 | 2.5% |
ANCA: anti-neutrophil cytoplasmic antibodies; HBV: hepatitis B virus.
Comparison of the frequencies of glomerular disease in patients with renal insufficiency at different times.
| Pathology type of glomerular disease | 2008–2012 | 2013–2017 | |
|---|---|---|---|
| Primary glomerulonephritis, | |||
| IgA nephropathy | 109 (27.3) | 118 (20.7) | |
| Membranous nephropathy | 27 (6.8) | 92 (16.2) | |
| Minimal change disease | 22 (5.5) | 48 (8.4) | .082 |
| Non-IgA mesangioproliferative glomerulonephritis | 38 (9.5) | 15 (2.6) | |
| Focal segmental glomerulosclerosis | 32 (8.0) | 42 (7.4) | .721 |
| Membranoproliferative glomerulonephritis | 16 (4.0) | 13 (2.3) | .123 |
| Crescentic glomerulonephritis | 13 (3.3) | 14 (2.5) | .462 |
| Endocapillary proliferative glomerulonephritis | 3 (0.8) | 9 (1.6) | .391 |
| Secondary glomerulonephritis, | |||
| Lupus nephritis | 56 (14.0) | 59 (10.4) | .085 |
| Henoch–Schönlein purpura nephritis | 9 (2.3) | 8 (1.4) | .324 |
| ANCA-associated systemic vasculitis | 15 (3.8) | 43 (7.6) | |
| Malignant nephrosclerosis | 17 (4.3) | 22 (3.9) | .765 |
| Benign arteriolar nephrosclerosis | 13 (3.3) | 25 (4.4) | .367 |
| Thrombotic microangiopathy | 1 (0.3) | 1 (0.2) | 1.000 |
| Diabetic nephropathy | 17 (4.3) | 43 (7.6) | |
| Light-chain deposition nephropathy | 2 (0.5) | 6 (1.1) | .563 |
| Renal amyloidosis | 5 (1.3) | 7 (1.2) | 1.000 |
| HBV-associated nephritis | 5 (1.3) | 4 (0.7) | .593 |
ANCA: anti-neutrophil cytoplasmic antibodies; HBV: hepatitis B virus. Data shown on bold are p < 0.05.
Figure 1.Percentage of elderly patients (≥60 years) during the period from 2008 to 2017.
Comparison of glomerular disease distribution in the elderly and nonelderly groups.
| Pathology type of glomerular disease | Elderly group | Nonelderly group | |
|---|---|---|---|
| Primary glomerulonephritis, | |||
| IgA nephropathy | 20 (11.6) | 207 (47.3) | |
| Membranous nephropathy | 66 (38.2) | 53 (12.1) | |
| Minimal change disease | 29 (16.8) | 41 (9.4) | |
| Non-IgA mesangioproliferative glomerulonephritis | 15 (8.7) | 38 (8.7) | .998 |
| Focal segmental glomerulosclerosis | 16 (9.2) | 58 (13.2) | .173 |
| Membranoproliferative glomerulonephritis | 13 (7.5) | 16 (3.7) | |
| Crescentic glomerulonephritis | 10 (5.8) | 17 (3.9) | .303 |
| Endocapillary proliferative glomerulonephritis | 4 (2.3) | 8 (1.8) | .697 |
| Secondary glomerulonephritis, | |||
| Lupus nephritis | 27 (31.8) | 31 (11.4) | |
| Henoch–Schönlein purpura nephritis | 1 (1.2) | 38 (13.9) | |
| ANCA-associated systemic vasculitis | 9 (10.6) | 29 (10.6) | .993 |
| Malignant nephrosclerosis | 2 (2.4) | 0 (0.0) | .088 |
| Benign arteriolar nephrosclerosis | 10 (11.8) | 105 (38.5) | |
| Thrombotic microangiopathy | 4 (4.7) | 13 (4.8) | .983 |
| Diabetic nephropathy | 19 (22.4) | 41 (15.0) | .114 |
| Light-chain deposition nephropathy | 3 (3.5) | 5 (1.8) | .614 |
| Renal amyloidosis | 8 (9.4) | 4 (1.5) | |
| HBV-associated nephritis | 2 (2.4) | 7 (2.6) | 1.000 |
ANCA: anti-neutrophil cytoplasmic antibodies; HBV: hepatitis B virus. Data shown on bold are p < 0.05.
Glomerular disease spectrum of patients with varying degrees of renal insufficiency.
| Pathology type | CKD5 | CKD4 | CKD3 | Total | |
|---|---|---|---|---|---|
| Primary glomerulonephritis, | |||||
| IgA nephropathy | 28 (12.5) | 41 (18.3) | 155 (69.2) | 224 (24.9) | .338 |
| Membranous nephropathy | 6 (5.0) | 22 (18.5) | 91 (76.5) | 119 (13.3) | |
| Minimal change disease | 5 (7.4) | 20 (29.4) | 43 (63.2) | 68 (7.6) | .185 |
| Non-IgA mesangioproliferative glomerulonephritis | 5 (9.4) | 9 (17.0) | 39 (73.6) | 53 (5.9) | .499 |
| Focal segmental glomerulosclerosis | 6 (8.2) | 11 (15.1) | 56 (76.7) | 73 (8.1) | .138 |
| Membranoproliferative glomerulonephritis | 5 (17.2) | 3 (10.3) | 21 (72.4) | 29 (3.2) | .218 |
| Crescentic glomerulonephritis | 11 (78.6) | 2 (14.3) | 1 (7.1) | 14 (1.6) | |
| Endocapillary proliferative glomerulonephritis | 0 (0.0) | 0 (0.0) | 11 (100) | 11 (1.2) | .081 |
| Secondary glomerulonephritis, | |||||
| ANCA-associated systemic vasculitis | 10 (32.3) | 13 (41.9) | 8 (25.8)*# | 31 (3.5) | |
| Malignant nephrosclerosis | 11 (47.8) | 3 (13.0) | 9 (39.1) | 23 (2.6) | |
| Benign arteriolar nephrosclerosis | 2 (5.4) | 10 (27.0) | 25 (67.6) | 37 (4.1) | .415 |
| Thrombotic microangiopathy | 0 (0.0) | 2 (100) | 0 (0.0) | 2 (0.2) | .062 |
| Lupus nephritis | 12 (11.1) | 30 (27.8) | 66 (61.1) | 108 (12.0) | .289 |
| Henoch–Schönlein purpura nephritis | 1 (5.9) | 3 (17.7) | 13 (76.5) | 17 (1.9) | .668 |
| Diabetic nephropathy | 5 (8.3) | 20 (33.3) | 35 (58.3) | 60 (6.7) | .074 |
| Light-chain deposition nephropathy | 1 (12.5) | 2 (25.0) | 5 (62.5) | 8 (0.9) | .876 |
| Renal amyloidosis | 0 (0.0) | 4 (33.3) | 8 (66.7) | 12 (1.3) | .401 |
| HBV-associated nephritis | 0 (0.0) | 1 (11.1) | 8 (88.9) | 9 (1.0) | .524 |
ANCA: anti-neutrophil cytoplasmic antibodies; HBV: hepatitis B virus; CKD3: GFR 30–59 ml/min/1.73 m2; CKD4: GFR 15–29 ml/min/1.73 m2; CKD5: GFR < 15 ml/min/1.73 m2. Data shown on bold are p < 0.05.
p < .05 for comparison with CKD5.
p < .05 for comparison with CKD4.
Figure 2.Five most frequently observed glomerular diseases among patients with different degrees of renal insufficiency. CKD3: GFR30-59 ml/min/1.73 m2; CKD4: GFR 15–29 ml/min/1.73 m2; CKD5: GFR < 15 ml/min/1.73 m2. IgAN: IgA nephropathy; LN: lupus nephritis; CreGN: crescentic glomerulonephritis; MANS: malignant nephrosclerosis; AASV: anti-neutrophil cytoplasmic antibodies associated systemic vasculitis; MN: membranous nephropathy; MCD: minimal change disease; DN: diabetic nephropathy; FSGS: focal segmental glomerulosclerosis.